The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Regression of cardiac hypertrophy in health and disease: mechanisms and therapeutic potential
Open accessAbstract
In this Review, the authors summarize the evidence for physiological and pathological cardiac hypertrophy regression from clinical and basic science studies, discussing therapies and mechanisms involved in regression of cardiac hypertrophy and highlighting knowledge gaps and questions for future investigation to design specific therapies to promote regression of pathological hypertrophy. Pathological cardiac hypertrophy is a leading risk factor for cardiovascular morbidity and mortality and is associated with increased fibrosis and apoptosis that lead to ventricular stiffness, risk of arrhythmia and impaired cardiac function. Partial reversal of cardiac hypertrophy occurs with many existing heart failure therapies, including renin–angiotensin–aldosterone system, β-adrenergic receptor, calcium-channel and SGLT2 antagonists, but is achieved in only a subset of patients. The potential for reverse remodelling in heart disease is influenced by many factors, including biological sex, genetics, duration of hypertension, BMI, age and disease aetiology. Exercise-induced and pregnancy-induced physiological cardiac hypertrophy is driven by cellular mechanisms distinct from those in pathological hypertrophy, and is completely reversible, whereas moderate exercise in heart failure antagonizes pathological cellular pathways and promotes hypertrophy regression. At the molecular level, hypertrophy regression is associated with metabolic shifts, reduced protein synthesis, extracellular matrix remodelling and altered activity of proteolytic pathways. Left ventricular hypertrophy is a leading risk factor for cardiovascular morbidity and mortality. Although reverse ventricular remodelling was long thought to be irreversible, evidence from the past three decades indicates that this process is possible with many existing heart disease therapies. The regression of pathological hypertrophy is associated with improved cardiac function, quality of life and long-term health outcomes. However, less than 50% of patients respond favourably to most therapies, and the reversibility of remodelling is influenced by many factors, including age, sex, BMI and disease aetiology. Cardiac hypertrophy also occurs in physiological settings, including pregnancy and exercise, although in these cases, hypertrophy is associated with normal or improved ventricular function and is completely reversible postpartum or with cessation of training. Studies over the past decade have identified the molecular features of hypertrophy regression in health and disease settings, which include modulation of protein synthesis, microRNAs, metabolism and protein degradation pathways. In this Review, we summarize the evidence for hypertrophy regression in patients with current first-line pharmacological and surgical interventions. We further discuss the molecular features of reverse remodelling identified in cell and animal models, highlighting remaining knowledge gaps and the essential questions for future investigation towards the goal of designing specific therapies to promote regression of pathological hypertrophy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Bristow, M. R., Saxon, L. A., Boehmer, J., Krueger, S., Kass, D. A., De Marco, T., Carson, P., DiCarlo, L., DeMets, D., White, B. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032423 · Cited by 5,812
Levy, D., Garrison, R. J., Savage, D. D., Kannel, W. B., & Castelli, W. P. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005313222203 · Cited by 5,699
Empagliflozin in heart failure with a preserved ejection fraction
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107038 · Cited by 4,874
Cardiac-Resynchronization Therapy for the Prevention of Heart-Failure Events
Moss, A. J., Hall, W. J., Cannom, D. S., Klein, H., Brown, M. W., Daubert, J. P., Estes, N. A. M., Foster, E., Greenberg, H., Higgins, S. L., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906431 · Cited by 3,157
Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system
Mehta, P. K., & Griendling, K. K. (2007) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00287.2006 · Cited by 1,924
Cells of the adult human heart
Litviňuková, M., Talavera-López, C., Maatz, H., Reichart, D., Worth, C. L., Lindberg, E. L., Kanda, M., Polanski, K., Heinig, M., Lee, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2797-4 · Cited by 1,729
Cardiac atrophy after bed rest and spaceflight
Perhonen, M. A., Franco, F., Lane, L. D., Buckey, J. C., Blomqvist, C. G., Zerwekh, J. E., Peshock, R. M., Weatherall, P. T., & Levine, B. D. (2001) · Journal of Applied Physiology · doi:10.1152/jappl.2001.91.2.645 · Cited by 494
Kokkinos, P. F., Narayan, P., Colleran, J. A., Pittaras, A., Notargiacomo, A., Reda, D., & Papademetriou, V. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511303332204 · Cited by 354
Myostatin/activin pathway antagonism: molecular basis and therapeutic potential
Han, H. Q., Zhou, X., Mitch, W. E., & Goldberg, A. L. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.05.019 · Cited by 314
Cited by
He, W., Wei, J., Liu, X., Zhang, Z., Huang, R., & Jiang, Z. (2024) · Scientific Reports · doi:10.1038/s41598-024-62465-6 · Cited by 30
Metadata
- Authors
- Martin, T. G., Juarros, M. A., & Leinwand, L. A.
- Venue
- Nature Reviews Cardiology
- Published
- 2023-01-04
- Volume
- 20
- Issue
- 5
- Pages
- 347-363
- ISSN
- 1759-5002 (ISSN-L)
- 1759-5010
- OpenAlex
- W4313455526
- Cited by
- 170
- References
- 16
- FWCI
- 13.34
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Regression of cardiac hypertrophy in health and disease: mechanisms and therapeutic potential. https://app.cochat.ai/papers/10.1038/s41569-022-00806-6
- The paper
- Martin, T. G., Juarros, M. A., & Leinwand, L. A. (2023). Regression of cardiac hypertrophy in health and disease: mechanisms and therapeutic potential. Nature Reviews Cardiology. https://doi.org/10.1038/s41569-022-00806-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.